Progenity to Present at the 2021 ICR Conference
January 05, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Expands Availability of COVID-19 PCR Testing Services Across United States
December 17, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
World Human Gene Sequencing Markets, Strategies & Trends Report 2021-2025: A Crowded, Growing Global Market with Complicated Packaging and Pricing is Emerging with Unlimited Growth Opportunities
December 15, 2020 04:53 ET
|
Research and Markets
Dublin, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The "Human Gene Sequencing Markets, Strategies & Trends. Forecasts by Hereditary, Newborn Screening, NIPT, Oncology, Pharmacogenomic, and Direct to...
Progenity Announces Closing of the Convertible Senior Notes Offering and Partial Exercise of the Initial Purchaser’s Option to Purchase Additional Notes
December 08, 2020 07:31 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...
Progenity Announces Closing of Public Offering of Common Stock
December 08, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity, Inc. Prices $75.0 Million Convertible Senior Notes Offering
December 02, 2020 23:51 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced the pricing of its offering of $75.0 million aggregate principal amount of 7.25% convertible senior notes...
Progenity Announces Pricing of Public Offering of Common Stock
December 02, 2020 23:50 ET
|
Progenity, Inc.
SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
Progenity Announces Proposed Convertible Senior Notes Offering
November 30, 2020 21:39 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (NASDAQ: PROG) today announced its intention to offer, subject to market and other conditions, $75 million aggregate principal amount of...
Progenity Announces Proposed Public Offering of Common Stock
November 30, 2020 21:38 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (NASDAQ: PROG), a biotechnology company with an established track record of success in developing and commercializing...
New Test for Triaging Preeclampsia Passes Key Development Milestone: Progenity Releases Prospective Clinical Verification Data for its Preecludia™ Test
November 20, 2020 07:30 ET
|
Progenity, Inc.
SAN DIEGO, Nov. 20, 2020 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing...